NCT03221582View on ClinicalTrials.gov

Impact of Hepatitis C Therapy and Bone Health

PHASE4TerminatedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

August 28, 2017

Primary Completion Date

November 26, 2018

Study Completion Date

November 30, 2018

Conditions
Human Immunodeficiency VirusHepatitis C
Interventions
DRUG

EBR/GZR

Elbasvir and Grazoprevir (EBR/GZR) tablet by mouth, once daily.

Trial Locations (1)

75216

Dallas VA Medical Center, Dallas

Sponsors
All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Dallas VA Medical Center

FED

NCT03221582 - Impact of Hepatitis C Therapy and Bone Health | Biotech Hunter | Biotech Hunter